



## PHARMACEUTICAL 2021









## PHARMACEUTICAL 2021



## Vanda Pharmaceuticals Inc. Rank 36 of 402



The relative strengths and weaknesses of Vanda Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Vanda Pharmaceuticals Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 81% points. The greatest weakness of Vanda Pharmaceuticals Inc. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 10% points.

The company's Economic Capital Ratio, given in the ranking table, is 262%, being 214% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	409,145
Cost of Goods Sold	0
Intangible Assets	21,559
Liabilities, Current	65,936
Liabilities, Non-Current	14,254
Other Assets	98,616
Other Compr. Net Income	-10
Other Expenses	33,160
Other Liabilities	0
Other Net Income	0
Other Revenues	252,584
Property and Equipment	4,136
Research and Development	55,577
Selling, General and Administrative Expense	140,510

Output Variable	Value in 1000 USD
Assets	533,456
Liabilities	80,190
Expenses	229,247
Revenues	252,584
Stockholders Equity	453,266
Net Income	23,337
Comprehensive Net Income	23,332
Economic Capital Ratio	262%

